The impact of disease and treatment on generic health-related quality of life in patients with hATTR amyloidosis: SF-36v2 results from a double-blind placebocontrolled trial of inotersen

被引：0
|
作者：
Yarlas, A. [1 ]
Kessler, A. Sikora [1 ]
Lovley, A. [1 ]
Guthrie, S. D. [2 ]
Pollock, M. [2 ]
Coelho, T. [3 ]
Conceicao, I. [4 ,5 ]
Obici, L. [6 ]
White, M. K. [1 ]
机构：
[1] Optum, Johnston, IA USA
[2] Akcea Therapeut, Boston, MA USA
[3] Hosp Santo Antonio, Ctr Study Amyloidoses, Porto, Portugal
[4] Hosp Santa Maria, CHLN, Lisbon, Portugal
[5] IMM, Clin & Translat Physiol Unit, Inst Physiol, Fac Med, Lisbon, Portugal
[6] Fdn IRCCS Policlin San Matteo, Amyloidosis Res & Treatment Ctr, Pavia, Italy
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2019年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO2291
引用
收藏
页码：717 / 717
页数：1
相关论文
共 50 条
  • [1] IMPACT OF INOTERSEN ON GENERIC HEALTH-RELATED QUALITY OF LIFE FOR PATIENTS WITH HATTR AMYLOIDOSIS: RESULTS FROM A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
    Yarlas, A.
    Kessler, Sikora A.
    Lovley, A.
    Guthrie, S.
    Pollock, M.
    White, M. K.
    [J]. VALUE IN HEALTH, 2018, 21 : S354 - S354
  • [2] ANALYSIS OF RESPONSES TO SF-36V2 ITEMS FOR PATIENTS WITH HATTR AMYLOIDOSIS: RESULTS FROM A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
    Yarlas, A.
    Kessler, Sikora A.
    Lovley, A.
    Guthrie, S.
    Pollock, M.
    White, M. K.
    [J]. VALUE IN HEALTH, 2018, 21 : S354 - S354
  • [3] IMPACT OF INOTERSEN ON CONDITION-SPECIFIC QUALITY OF LIFE (QOL) FOR PATIENTS WITH HATTR AMYLOIDOSIS: RESULTS FROM A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
    Kessler, Sikora A.
    Yarlas, A.
    Lovley, A.
    Guthrie, S.
    Pollock, M.
    White, M. K.
    [J]. VALUE IN HEALTH, 2018, 21 : S354 - S354
  • [4] Health-related quality of life in Switzerland: normative data for the SF-36v2 questionnaire
    Roser, Katharina
    Mader, Luzius
    Baenziger, Julia
    Sommer, Grit
    Kuehni, Claudia E.
    Michel, Gisela
    [J]. QUALITY OF LIFE RESEARCH, 2019, 28 (07) : 1963 - 1977
  • [5] Health-related quality of life in Switzerland: normative data for the SF-36v2 questionnaire
    Katharina Roser
    Luzius Mader
    Julia Baenziger
    Grit Sommer
    Claudia E. Kuehni
    Gisela Michel
    [J]. Quality of Life Research, 2019, 28 : 1963 - 1977
  • [6] Psychometric testing of the health-related quality of life measurement, SF-36v2, in the general population of Thailand
    Kangwanrattanakul, Krittaphas
    Auamnoy, Titinun
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (03) : 313 - 320
  • [7] Health-related quality of life in Welsh adults: psychometric properties of the SF-36v2 and normative data
    Alzahrani, H.
    Alshehri, Y. S.
    Barcaccia, Barbara
    Alshehri, M. A.
    Alzhrani, M.
    Bjorner, J. B.
    [J]. PUBLIC HEALTH, 2023, 214 : 153 - 162
  • [8] Impact of Inotersen on Subgroups of Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial
    Yarlas, Aaron
    Merlini, Giampaolo
    White, Michelle K.
    Kessler, Asia Sikora
    Lovley, Andrew
    Guthrie, Spencer D.
    Pollock, Michael
    Gertz, Morie A.
    [J]. BLOOD, 2018, 132
  • [9] Long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open-label extension of the NEURO-TTR trial
    Karam, Chafic
    Brown, Duncan
    Yang, Min
    Done, Nicolae
    Zhu, Jing Jing
    Greatsinger, Alexandra
    Bozas, Ana
    Vera-Llonch, Montserrat
    Signorovitch, James
    [J]. MUSCLE & NERVE, 2022, 66 (04) : 438 - 446
  • [10] Impact of Inotersen on Functioning and Activities of Daily Living for Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial
    Yarlas, Aaron
    Merlini, Giampaolo
    White, Michelle K.
    Kessler, Asia Sikora
    Lovley, Andrew
    Guthrie, Spencer D.
    Pollock, Michael
    Gertz, Morie A.
    [J]. BLOOD, 2018, 132
12345